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Abstract
Background:  Familial Alzheimer's disease-linked variants of presenilin (PSEN1 and PSEN2)
contribute to the pathophysiology of disease by both gain-of-function and loss-of-function
mechanisms. Deletions of PSEN1  and  PSEN2  in the mouse forebrain result in a strong and
progressive neurodegenerative phenotype which is characterized by both anatomical and
behavioral changes.
Results: To better understand the molecular changes associated with these morphological and
behavioral phenotypes, we performed a DNA microarray transcriptome profiling of the
hippocampus and the frontal cortex of the PSEN1/PSEN2 double knock-out mice and littermate
controls at five different ages ranging from 2–8 months. Our data suggest that combined
deficiencies of PSEN1 and PSEN2 results in a progressive, age-dependent transcriptome signature
related to neurodegeneration and neuroinflammation. While these events may progress differently
in the hippocampus and frontal cortex, the most critical expression signatures are common across
the two brain regions, and involve a strong upregulation of cathepsin and complement system
transcripts.
Conclusion: The observed neuroinflammatory expression changes are likely to be causally linked
to the neurodegenerative phenotype observed in mice with compound deletions of PSEN1 and
PSEN2. Furthermore, our results suggest that the evaluation of inhibitors of PS/γ-secretase activity
for treatment of Alzheimer's Disease must include close monitoring for signs of calpain-cathepsin
system activation.
Background
Presenilins (PS) are highly homologous polytopic mem-
brane proteins that play a critical role in intramembra-
nous processing of amyloid precursor proteins (APP),
leading to the production of Aβ peptides (for reviews, see
[1-4]). Inheritance of mutations in PSEN1 and PSEN2,
that encode PS1 and PS2, respectively, cause familial
forms of Alzheimer's disease (FAD) [5,6], and do so by
elevating the ratio of Aβß42/Aβ40 peptides [7-10]. Hence,
it has been argued that FAD-linked PS1 variants cause dis-
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ease primarily through a gain of function mechanism.
However, recent studies have shown that these PS variants
also result in a significant loss of γ-secretase function that
may critically contribute to the pathophysiology of FAD
(for a review, see [11]).
Over the last several years we assessed the gene expression
profiles of PSEN1  knockout mice and PSEN1  mutant
transgenic animals, and have defined a set of PSEN1-
dependent genes [12-15]. However, it is important to
point out that due to redundant functions and distribu-
tions of PSEN1 and PSEN2 [16,17], cortical PSEN1 abla-
tion in mice results in only a limited phenotype. In
contrast, forebrain PSEN1/PSEN2 double KO mice show a
strong and progressive neurodegenerative phenotype
which is characterized by both anatomical and behavioral
changes [11,18]. Although anatomical changes are not
apparent at 2 months of age, these mice already show
mild memory impairments at this age. The behavioral
phenotype progresses with time and the mutant mice
begin to exhibit excessive grooming behavior, increased
stereotypy in the open field, and reduced latency in the
rotarod test at the age of 6 months [18]. The anatomical
changes develop over time, and the progressive thinning
of cortical layers becomes prominent by the age of 6
months.
To gain a better understanding of presenilin-dependent
neurodegeneration in the cortex, we performed an expres-
sion profiling of the hippocampus (HC) and frontal cor-
tex (FC) of mice with forebrain ablations of PSEN1 and
PSEN2. We used DNA microarrays to analyze the tran-
scriptome at five developmental time points. We chose to
examine the temporal nature of gene expression changes
because the PSEN1  allele is conditionally deleted by a
CamKII-cre allele that promotes recombination of
"floxed" loci first in the hippocampus, and then spreads
throughout the entire forebrain. We focused our attention
on the following questions: 1) what are the gene expres-
sion consequences of PSEN1/PSEN2 ablation; 2) do the
altered genes share common functional characteristics; 3)
how does gene expression change over time as a function
of PSEN1/PSEN2 deletion; 4) are the molecular signatures
of neurodegeneration similar in the HC and FC and 5) is
presenilin-dependent molecular neurodegeneration pro-
gressing similarly in FC and HC?
Results
The experimental design and analysis strategy are outlined
in Figure 1. Briefly, frontal and hippocampal cortices of
PSEN1/PSEN2 KO (PSKO) and matched control animals
of different postnatal ages were analyzed by MG_430 oli-
gonucleotide arrays by Affymetrix. An RMA-based nor-
malization was followed by a multi-level analysis that
Experimental Design Figure 1
Experimental Design. The frontal cortical (FC) and hippocampal (HC) transcriptome of PS1/PS2 double-knockout animals 
(KO) was compared to that of wild-type controls (WT) using Affymetrix oligonucleotide microarrays. The samples from 5 dif-
ferent ages for each microarray were prepared from a pool of 3 animals. Data were GCOS segmented, gcRMA normalized and 
compared using several experimental paradigms, all employing pairwise comparison statistics.Molecular Neurodegeneration 2008, 3:14 http://www.molecularneurodegeneration.com/content/3/1/14
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compared the samples based on the genotype, age and
brain region.
Gene expression differences regardless of brain region or 
age
In a genotype-driven analysis we observed a strong tran-
scriptome signature between the PSKO and CNT mice.
113 DNA microarray probesets showed significant gene
expression differences (|ALR| > 0.585, p < 0.05). Of these,
41 probes reported underexpression, while 72 showed
upregulation in the PSKO animals, suggesting that the
removal of the PS genes is characterized by a complex set
of transcriptional events (Additional File 1). Two-way
hierarchical clustering of the differentially expressed
probe sets revealed a separation of samples according to
genotype (Additional File 2). As the altered gene expres-
sion products performed a wide variety of cellular func-
tions, we subjected this dataset to a pathway analysis
based on predefined cellular processes (BioCarta). This
analysis revealed that the PSKO animals showed a statisti-
cally significant populational downregulation of tran-
scripts related to the GABA pathway and GPCR function,
while 12 pathways showed upregulation in the PSKO
sample (Table 1). Notably, the increased transcript net-
works strongly suggest and ongoing inflammation and/or
neurodegeneration in the experimental animals (e.g. CAL-
PAIN, TOB1, TGFβ and other related pathways – see Addi-
tional File 3 for complete analysis results). This initial
analysis was followed by a region*genotype assessment.
Gene expression differences in the frontal cortex (FC)
In the region*genotype  assessment the FC of PSKO and
CNT mice reported 73 differentially expressed probesets
(|ALR| > 0.585, p < 0.05; Additional File 4). Importantly,
the distribution of these expression changes was highly
skewed. Of the 73 probesets 70 reported an upregulation
(96%), while only 2 probesets were downregulated (4%).
The clustering of these data also separated the FC samples
according to their proper genotype (Figure 2).
Table 1: Differentially expressed gene groups between the PSKO and CNT mice regardless of age or brain region.
# NAME SIZE ES NES p-val q-val
1 GABAPATHWAY 11 0.68 1.59 0.046748 0.147418
2 AGPCRPATHWAY 10 0.67 1.45 0.019068 0.243600
3 RAC1PATHWAY 21 -0.59 -1.30 0.020121 0.418927
4 D4GDIPATHWAY 10 -0.68 -1.31 0.043478 0.397110
5 ALKPATHWAY 32 -0.55 -1.34 0.014085 0.298667
6 NTHIPATHWAY 19 -0.61 -1.35 0.040936 0.290866
7 TGFBPATHWAY 13 -0.67 -1.42 0.010142 0.163844
8 MCALPAINPATHWAY 22 -0.53 -1.44 0.005848 0.179323
9 INTRINSICPATHWAY 20 -0.58 -1.45 0.020534 0.177983
10 LAIRPATHWAY 10 -0.67 -1.45 0.046185 0.198237
11 VITCBPATHWAY 10 -0.51 -1.45 0.038776 0.228195
12 TOB1PATHWAY 14 -0.73 -1.63 0.004082 0.087297
13 EXTRINSICPATHWAY 12 -0.71 -1.69 0.014614 0.082402
14 NKCELLSPATHWAY 15 -0.50 -1.70 0.025490 0.138997
The whole dataset was subjected to pathway analysis with BioCarta using GSEA. Significantly enriched pathways are presented in either direction 
(positive NES – enriched in CNT; negative NES – enriched in PSKO). Abbreviations: SIZE- number of non-redundant probes in a pathway; ES – 
enrichment score; NES – normalized enrichment score; p-val – groupwise p value; q-val – groupwise false discovery ratio estimate. Note that only 
2 pathways were enriched in the CNT mice (GABA and AGPCR), while the PSKO mice samples were enriched in 12 pathways.Molecular Neurodegeneration 2008, 3:14 http://www.molecularneurodegeneration.com/content/3/1/14
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Gene expression differences in the hippocampus (HC)
In the region*genotype assessment of the HC of PSKO and
CNT mice, we did not observe a dominant downregula-
tion of transcripts. Rather, the HC of PSKO and CNT mice
reported an opposite pattern of that seen in the FC: of the
137 probesets reporting an expression difference in HC
only 37 (26%) reported an upregulation while 101 (74%)
probesets showed an underexpression in the experimental
animals (Additional File 5). Notably, the distribution of
the HC expression changes was also highly skewed, but in
the opposite direction from that observed in the FC.
Finally, the clustering of these data in the vertical dimen-
sion also separated the HC of the PSKO samples from
those of matched controls (Figure 3).
Gene expression similarities and differences in the FC and 
HC of PSKO mice
Although the most significant changes were different in
the FC and HC, the overall gene expression patters were
very much alike across the two brain regions. The magni-
tude of change between the PSKO and WT mice (ALR) of
the 73 genes probesets that were found differentially
expressed in the FC were very highly correlated with the
gene expression changes observed in the HC (r = 0.89, p <
0.001) (Figure 4A). Similarly, the 137 gene probesets that
showed differential expression in the HC of PSKO and WT
mice also showed a correlation with the expression
changes for same genes in the FC (Figure 4B). This corre-
lation of the HC to FC correlation was somewhat weaker
(r = 0.64, p < 0.01) than that observed for the FC to HC
differentially expressed probesets.
Finally, we observed two important gene families that
were differentially expressed both in the FC and the HC
(Figure 5). Five members of the cathepsin and five mem-
bers of the complement gene families showed a progressive,
age-dependent overexpression in the PSKO mice. The pro-
gression of this overexpression was similar in time course
Figure 2
Hierarchical clustering of genes that show differential expres- sion in the FC of PSKO and CNT mice Figure 2
Hierarchical clustering of genes that show differen-
tial expression in the FC of PSKO and CNT mice. The 
numerical data are presented in Additional File 4. Gene 
probes are clustered in rows (denoted by symbols and probe 
identifiers), microarrays are clustered in columns (denoted 
by sample identifiers). Each pixel represents a single, color-
coded gene expression value form FC form a PSKO or CNT 
mouse sample at five developmental ages. Shades of red cor-
respond to the magnitude of expression increase, the inten-
sity of blue corresponds to the magnitude of the reduction in 
gene transcripts. Note that the frontal cortical PSKO and 
CNT samples, regardless of developmental age, cluster on 
different ends of the dendrogram.Molecular Neurodegeneration 2008, 3:14 http://www.molecularneurodegeneration.com/content/3/1/14
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and magnitude across the FC and HC. Furthermore, in
addition to the increased transcript levels, two investi-
gated genes, Ctsd and C1q showed the predicted, progres-
sive induction in protein expression on a Western blot in
a new set of experimental and control animals (Figure 6).
To determine if this was a true upregulation in the PSKO
samples or it represented a failure to downregulate expres-
sion levels as part of normal development, we examined
the normal developmental expression levels of these
genes in the CNT mice (Additional File 6). As the expres-
sion levels of all these genes were stable in the tested age
range (2–8 months) in both the FC and HC, we can con-
clude that the observed overexpression is indeed a result
of an active transcriptional upregulation in the PSKO
brain samples.
Discussion
Over the past few years, we have used gene microarray
strategies to examine transcript levels in brains of mice
with conditionally inactivated PSEN1 (cPS1 KO) alleles.
While these studies have proven informative, redundant
function and distribution of PSEN1 and PSEN2 in hippoc-
ampus and cortex [16,17] has limited the interpretation of
our findings. Indeed, while cPS1KO mice fail to exhibit
any neuroanatomical or behavioral alterations [19,20],
cPS1KO mice on a PSEN2 KO background show a strong
and progressive neurodegenerative phenotype that is
characterized by both anatomical and behavioral changes
[11,18]. These animals do not exhibit anatomical changes
at 2 months of age, yet show mild memory impairments
at this age. The behavioral phenotypes progress over time
and are paralleled by considerable cortical atrophy and
neurodegeneration. In the present study, we performed
expression profiling in order to develop an understanding
of the mechanism(s) that might mediate these morpho-
logical and behavioral observations, and we now offer
several novel insights. First, we show that simultaneous
ablation of PSEN1 and PSEN2 leads to a wide variety of
gene expression changes that progress over time. Second,
the frontal cortex and hippocampus are both affected in
PSKO brains, albeit by the notable difference that gene
expression changes in the FC are characterized by elevated
transcript levels, while the HC is mostly characterized by
reduced transcript levels. Third, the transcriptome
changes suggest a progressive neurodegenerative process
with strong immune system activation. Fourth, based on
the BioCarta pathway analysis, it appears that GABA-ergic
Figure 3
Hierarchical clustering of genes that show differential expres- sion in the HC of PSKO and CNT mice Figure 3
Hierarchical clustering of genes that show differen-
tial expression in the HC of PSKO and CNT mice. 
The numerical data are presented in Additional File 5. Gene 
probes are clustered in rows (denoted by symbols and probe 
identifiers), while microarrays are clustered in columns 
(denoted by sample identifiers). Figure layout similar to that 
in Figure 2. Note that the frontal cortical PSKO and CNT 
samples, regardless of developmental age, cluster on different 
ends of the dendrogram.Molecular Neurodegeneration 2008, 3:14 http://www.molecularneurodegeneration.com/content/3/1/14
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HC and FC expression changes are highly correlated Figure 4
HC and FC expression changes are highly correlated. Both plots denote the ALRPSKO-CNT in the HC (X axis) and FC (Y 
axis). Each blue diamond represents a single, differentially expressed gene probe. Red dashed line denotes linear regression of 
the dataset. A. PSKO FC samples reported 70 genes differentially expressed form the FC of CNTs. These genes also showed a 
highly correlated expression pattern in the HC comparison (Pearson r = 0.89, p < 0.001) B. PSKO HC samples reported 53 
genes differentially expressed form the HC of CNTs. These genes also showed a highly correlated expression pattern in the 
FC comparison (Pearson r = 0.67, p < 0.005).
PS ablation-dependent expression changes in cathepsin and complement transcripts as a function of postnatal age Figure 5
PS ablation-dependent expression changes in cathepsin and complement transcripts as a function of postnatal 
age. The expression changes of 5 cathepsin (Ctsc, Ctsd, Ctsh, Ctss and Ctsz) and 5 complement system transcripts (C1qa, C1qb, 
C1qc, C3ar1 and C4b) were examined in more detail. In both graphs X axis denotes age of mice, while Y axis denotes pairwise 
expression difference between the PSKO mice and matched WT samples. Each color line represents change in expression 
over time for a single gene. A) FC. B) HC. Note the similarity of the age-dependent transcript increase in the PSKO animals 
across the two brain regions.Molecular Neurodegeneration 2008, 3:14 http://www.molecularneurodegeneration.com/content/3/1/14
Page 7 of 11
(page number not for citation purposes)
neurons may be a preferential early target of the neurode-
generative events. Fifth, the Complement and Cathepsin sys-
tems appear to be critical contributors to
neurodegeneration in both the hippocampus and frontal
cortex.
One of the most intriguing findings of the manuscript is
that transcript repressions dominate in the FC, while tran-
script inductions are the hallmark of the HC tissue.
Although the most prominent presenilin deletion
induced transcript changes may be different between
these two brain regions, the deletion signature of the FC
expression change was strong in HC and vice versa. We
interpret these findings that the neurodegenerative events
in FC lag behind of those in HC, suggesting that the early
stages of degeneration are characterized by a strong, wide-
spread repression of mRNA species. However, as the
pathophysiological process proceeds, in addition to the
transcript repression, a de novo inflammation-related tran-
script induction occurs, which becomes a dominant fea-
ture of a gene expression profile in the HC. Alternatively,
the differential cytoarchitecture and molecular composi-
tion of FC and HC provide a differential framework for
the adaptational responses of these two brain regions, and
results in a different gene expression profile.
Presenilins associate with Aph1, Pen2 and Nicastrin in a
large complex that mediates intramembranous, "γ-secre-
tase" [1] proteolysis of a variety of type-I membrane pro-
teins, including Notch, APP, E-cadherins, N-cadherins,
and p75NTR, amongst others (reviewed by [21]). For
most of these proteins, γ-secretase-mediated processing
results in the generation of intracellular derivatives,
termed ICDs, that have been shown to initiate complex
signaling cascades, including those involved in cell adhe-
sion, lateral inhibition of cell fate decisions, neurotrophin
signaling and cell differentiation [22,23]. It has also
become increasingly evident that PS have functions that
go beyond their role as the catalytic entity of γ-secretase
activity. For example, PS located in the endoplasmic retic-
ulum (ER) and Golgi apparatus regulate calcium homeos-
tasis [24], findings that may be equally relevant for
Age-dependent upregulation of C1q and Ctsd in PS knockout mice Figure 6
Age-dependent upregulation of C1q and Ctsd in PS knockout mice. The same nitrocellulose membrane was re-
probed for Ctsd, C1q, and Tubulin. Note a progressive, age-dependent upregulation of C1q and Ctsd in the KO mice but not the 
matched wild-type controls. Tubulin was used as a loading control. Molecular weights of Ctsd species correlate best to active 
intermediate (48 kD) and mature heavy chain (34 kD).Molecular Neurodegeneration 2008, 3:14 http://www.molecularneurodegeneration.com/content/3/1/14
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neurodegeneration observed in the PSKO mice. Not sur-
prisingly, with increasing age, the PSKO mice develop
striking neurodegeneration of the cerebral cortex and
worsening impairments of memory and synaptic function
[18]. However, it is important to point out that gene
expression changes arise before noticeable anatomical
neurodegeneration. The progressive gene expression
changes that we observed in both hippocampus and fron-
tal cortex also appear to suggest that the cortical GABA-
ergic interneurons may be one of the early targets of neu-
rodegeneration mediated by the ablation of PSEN genes.
As the GABA-ergic system has a strong influence on cogni-
tive behaviors [25,26], the expression changes in
interneurons are likely to be related to the altered cogni-
tive processes reported in these mice. On the other hand,
interneurons have been shown to exhibit enhanced vul-
nerability to various insults [27]. These events likely result
in necrosis-induced microglial activation, accompanied
by overexpression of the complement system transcripts,
leading to neuroinfammatory processes [28], thus further
accelerating the neurodegenerative processes.
The mechanism(s) by which ablation of PSEN genes leads
to neurodegeneration are not fully understood, but likely
involve several converging pathways. In this regard, our
dataset is highly informative: first, we observe a strong
and progressive increase in expression of transcripts
encoding molecules in the calpain-cathepsin system.
These results confirm and expand the previously reported
upregulation of Cathepsin S in these mice [29]. Both cal-
pains and cathepsins belong to the papain superfamily of
cysteine proteases that are primarily localized in lyso-
somes and are critical for intracellular protein catabolism.
Calpain-mediated extralysosomal release of cathepsins is
a critical event in necrosis, and cathepsin inhibitors show
strong neuroprotection in models of acute neuronal
insults [30,31]. Thus, we propose that neurodegeneration
in these mice is a result of a progressive neuronal calpain-
cathepsin system activation over time. How does loss of
PS function lead to induction of the calpain-cathepsin sys-
tem? We offer two proposals that are not mutually exclu-
sive. In the first, we suggest that in the absence of PS/γ-
secretase activity, extremely high levels of membrane-teth-
ered stubs derived from type 1 membrane proteins hyper-
accumulate in endosomal-lysosomal compartments,
hence "saturating" those proteases that would otherwise
be necessary for maintaining intracellular homeostasis. In
this setting, the induction of the calpain-cathepsin system
would thus reflect a compensatory mechanism. This
hypothesis is consistent with the model that a function of
PS/γ-secretase is to serve as a membrane-bound proteo-
some that promotes intramembranous proteolysis in
order to enhance clearance of membrane-tethered stubs
derived from ectodomain shedding of type 1 membrane
proteins [32]. Indeed, we have shown that cultured mam-
malian cells expressing dominant-negative PS1 variants
harboring mutations at the critical aspartate 257 and 385
residues necessary for γ-secretase activity, exhibit unusual
accumulations of distended intramembranous organelles
resembling multivesicular bodies that are immunoreac-
tive with antibodies specific for membrane-tethered stubs
[33]. The second model to explain our findings is in the
absence of PS expression, the cell surface levels of recep-
tors and ion channels in either pre- or postsynaptic mem-
branes is altered in manner that gives rise to inappropriate
signaling events and alterations in calcium homeostasis.
In support of this notion, we [33] and others [34] have
shown that cells that express dominant-negative forms of
PS1 or that lack PSEN alleles, respectively, exhibit elevated
levels of a variety of type I membrane proteins and their
membrane-tethered stubs.
Inhibition of PS/γ-secretase activity has been debated as a
promising therapeutic strategy for treatment of Alzhe-
imer's Disease [35,36]. In this context, our results offer a
cautionary note and suggest that the preclinical evaluation
of such agents should include close monitoring for signs
of calpain-cathepsin system activation, and development
of a peripheral tissue assays on the complement-cathepsin
system expression as informative tools for assessment of
potential adverse effects that may also be present is the
CNS.
Methods
A. Experimental animals
To generate forebrain-specific PS conditional double
knockout (PSKO) mice, we crossed floxed PS1 (fPS1),
αCaMKII-Cre transgenic [19,37,38] and PS2-/- [39] mice
together to obtain fPS1/fPS1;αCaMKII-Cre;PS2-/- mice.
All experimental procedures were reviewed and approved
by Institutional Animal Care and Use Committee
(IACUC) of the University of Chicago (Protocol #s 71434
and 70958).
B. Sample preparation and hybridization
Hippocampi and frontal cortices were rapidly dissected
and frozen on dry ice and stored at -80°C until RNA iso-
lation. Total RNA was isolated using the Trizol reagent.
RNA quality was assessed using the Agilent Bioanalyzer.
All samples reported an RNA Integrity Number (RIN) >
8.0. Reverse transcription, in vitro transcription and frag-
mentation were performed according to manufacturer's
recommendation http://www.affymetrix.com. FC and HC
samples for microarray analysis were generated by pool-
ing RNA from 3 animals from appropriate genotypes and
ages. Samples were hybridized onto MG_430 mouse
Affymetrix GeneChips. Microarrays were considered for
use only if the average 3':5' ratio for GAPDH and actin did
not exceed 1:1.2. Segmentation of scanned microarray
images was performed by MAS5. Determination of expres-Molecular Neurodegeneration 2008, 3:14 http://www.molecularneurodegeneration.com/content/3/1/14
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sion levels and scaling were performed using gcRMA in
GenePattern [40].
C. Data analysis
Identification of differentially expressed genes
i) Comparison of all KO animals to matched WT regard-
less of age or brain region. We identified genes as differen-
tially expressed in the PSKO samples showed a pairwise
difference > 50% (|ALR| > 0.585) at p < 0.05 to the
matched WT controls. In this comparison a matched pair-
wise comparison eliminates the effects that are due to
robust differences in the developmental age and brain
region.
ii) Comparison of all HCKO animals to matched HCWT.
We identified genes as differentially expressed in the
HCKO samples showed a pairwise difference > 50% (|ALR|
> 0.585) at p < 0.05 in the matched WT controls. In this
comparison a matched pairwise comparison eliminated
the effects due to developmental age.
iii) Comparison of all FCKO animals to matched FCWT. The
comparison was performed in a similar fashion to that
described for the HC samples.
Pathway analyses
These analyses were performed on the whole dataset using
GSEA 2.0 [41] and the preset pathways from BioCarta
(ref). Enrichment in a pathway was considered significant
if it reached a p < 0.01 at a q < 0.05 (FDR < 5%).
Correlations
Correlations were calculated using Pearson r value for the
log2 ratios between the two compared conditions.
Clustering
Two-way clustering (sample and gene vectors) was per-
formed on gcRMA generated log2-transformed expression
levels using Euclidian distance in GSEA.
Data sharing
The gcRMA normalized microarray dataset, together with
the previous PS1 KO and TG datasets [12-15] is available
for download from http://mirnicslab.vanderbilt.edu/mir
nicslab. Forthermore, the data will be deposiet in a
MIAME/MGED format into the NCBI Gene Expression
Omnibus database at the time of publication.
D. Western blots
A new set of control and experimental animals was used
in this study. 100 ug of cortical brain homogenate was run
on 12% SDS-PAGE under reducing conditions, trans-
ferred to nitrocellulose and probed for C1q (1:800).
Membranes were stripped and re-probed for Cathepsin D
(1:10,000) and tubulin (loading control). For each, mem-
branes were blocked with 5% milk in tris-buffered saline
with 0.1% tween-20 (TBST), incubated with primary anti-
body overnight at 4°C, washed and incubated in HRP-
conjugated secondary antibody for 1 hour at room tem-
perature. Blots were exposed using ECL substrate and a
Chemidoc XRS imager (Bio-Rad). Cathepsin D antibody
[42] was obtained from Dr. Ralph Nixon (New York Uni-
versity), while C1q antibody [43,44] was provided by Dr.
Andrea J. Tenner (U of California at Irvine). Molecular
weights of Ctsd species correlate best to active intermedi-
ate (48 kD) and mature heavy chain (34 kD) [45].
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Gene expression differences between PSKO and CNT mice regardless 
of age or brain region. A gene probe was differentially expressed if it 
reported an > 50% change (|ALR| > 0.585) at a pairwise t-test p < 0.05 
between all the PSKO and CNT samples. 72 genes were upregulated, 
while 41 genes showed reduction in the PSKO samples. The probes from 
this list are clustered in Additional File 2.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1750-
1326-3-14-S1.pdf]
Additional file 2
Hierarchical clustering of genes that show differential expression 
between PSKO and CNT mice regardless of age or brain region. The 
numerical data are presented in Additional File 1. Gene probes are clus-
tered in rows (denoted by symbols and probe identifiers), microarrays are 
clustered in columns (denoted by sample identifiers). Each pixel represents 
a single, color-coded gene expression value form FC or HC form a PSKO 
or CNT mouse sample at five developmental ages. Shades of red corre-
spond to the magnitude of expression increase; the intensity of blue corre-
sponds to the magnitude of the reduction in gene transcripts. Note that the 
PSKO and CNT samples, regardless of developmental age or brain region, 
cluster on different ends of the dendrogram.
Click here for file
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